Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This compound is a synthetic small molecule belonging to the class of hybrid peptides. It features a diazepane core substituted with an amino-trifluorophenyl butanoyl group. The structure and related intermediates are associated with research into dipeptidyl peptidase IV (DPP-IV or DPP4) inhibition—a mechanism relevant for antidiabetic drugs such as sitagliptin. However, this specific compound is primarily referenced in chemical and pharmacological databases as an experimental or research molecule rather than a marketed pharmaceutical product[1][8]. Its main scientific interest lies in its potential as a selective DPP-IV inhibitor.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on (3R)-4-[(3R)-3-amino-4-(2,4,5-trifluorophenyl)butanoyl]-3-methyl-1,4-diazepan-2-one.